No FDA pre-market approval is required to sell a tranexamic acid eye cream in the United States, provided the product is positioned and labeled as a cosmetic. The FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which added significant new requirements but does not require pre-approval for cosmetics.
Under MoCRA, all cosmetic facilities that manufacture or process cosmetics for U.S. distribution must register with the FDA, and all cosmetic products must be listed through the FDA's registration portal. These requirements phased in starting December 2023 for large companies and December 2024 for small businesses. Your contract manufacturer should already have their facility registration in place; confirm this before signing any production agreement.
MoCRA also requires that brands maintain safety substantiation records — documentation that the product is safe for its labeled use — and that there is an adverse event reporting mechanism in place. For an eye-area leave-on product, safety substantiation typically includes the manufacturer's raw material safety data, formulation stability data, and where available, human tolerance testing.
The boundary that brands must not cross is a drug claim. If your eye cream labeling or marketing implies that the product treats, prevents, or cures a condition — for example, "treats periorbital hyperpigmentation" or "corrects dark circles caused by vascular dysfunction" — the FDA may classify the product as a drug, triggering pre-market approval requirements and manufacturing standards under 21 CFR Part 211. "Visibly reduces the appearance of dark circles" is cosmetic language. "Treats dark circles" is not.
For sales in California, Prop 65 requires a warning label if the product contains any listed chemical above safe harbor levels. Your manufacturer should provide a Prop 65 compliance review as part of their documentation package.
If you plan to sell in both the U.S. and EU simultaneously, factor in the EU Cosmetic Product Safety Report (CPSR) requirement, which must be completed by a qualified safety assessor and submitted to the Responsible Person before market entry. This adds cost but is mandatory and non-negotiable for EU distribution.
Ingredients in this answer: Tranexamic Acid
Read the full guide on Private Label Tranexamic Acid Eye Cream Manufacturer Low MOQ →